Challenges and opportunities of adding CFTR modulators for cystic fibrosis to the WHO essential medicines list

Enrico Costa, Hendrika A van den Ham*, Hubert G M Leufkens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)920-922
Number of pages3
JournalJournal of Cystic Fibrosis
Volume24
Issue number5
Early online date4 Jul 2025
DOIs
Publication statusPublished - Sept 2025

Keywords

  • CFTR modulators
  • Cystic fibrosis
  • Elexacaftor/tezacaftor/ivacaftor
  • Equitable access
  • Essential medicines
  • Essential medicines list
  • Global Health
  • Medicines affordability
  • World health organization

Cite this